- Home
- / ImmuCell
ImmuCell
Stock Price
$3.6
2024-10-29
Market Capitalization
$28.1 M
2024-10-29
Revenue
$27.6 M
FY, 2025
ImmuCell Summary
Company Summary
- Overview
- ImmuCell is an animal health company that develops, manufactures, and markets products that improve health and productivity in the dairy and beef industries. It produces products the First Defense product line that provides immediate immunity to newborn dairy and beef cattle against E. coli, coronavirus, and rotavirus infections.
- Type
- Public
- Status
- Active
- Founded
- 1982
- HQ
- Portland, ME, US | view all locations
- Website
- http://immucell.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Bobbi Jo Brockmann, Vice President of Sales and Marketing, Director
Steven T. Rosgen, Director
Paul R. Wainman, Director
Operating MetricsView all
Patents (US)
2
FY, 2020
Trademarks (US)
13
FY, 2020
Facility Space, sq. ft.
35K
FY, 2020
LocationsView all
1 location detected
Portland, ME HQ
United States
56 Evergreen Dr
ImmuCell Financials
Summary Financials
- Revenue (FY, 2025)
- $27.6M
- Gross profit (FY, 2025)
- $11.4M
- Net income (FY, 2025)
- ($1.0M)
- Cash (FY, 2025)
- $3.8M
- EBIT (FY, 2025)
- $1.6M
- Enterprise value
- $37.5M